MedDataX Logo

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

NCT ID: NCT00643760

Last Updated: 2013-07-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

421 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

NCT00619476

Neuralgia, Postherpetic
COMPLETED PHASE2

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

NCT00617461

Neuralgia, Postherpetic
COMPLETED PHASE2

A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)

NCT00156078

Diabetic Neuropathy, Painful
COMPLETED PHASE4

Pregabalin Peripheral Neuropathic Pain Study

NCT00141219

Diabetic Neuropathies Neuralgia
COMPLETED PHASE3

Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management

NCT01364298

Diabetic Peripheral Neuropathic Pain
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a dose-response study of XP13512 compared with concurrent placebo control and LYRICA (pregabalin), in subjects with neuropathic pain associated with DPN. Three doses of XP13512 (1200 mg/day, 2400 mg/day and 3600 mg/day) are being evaluated for the management of neuropathic pain associated with DPN. Approximately 392 subjects from 70 to 80 participating sites in the US will be randomized to receive either XP13512 at the above mentioned doses, placebo or pregabalin (300mg/day).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathy, Diabetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo

Pregabalin

Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks

Group Type OTHER

Pregabalin

Intervention Type DRUG

pregabalin 300mg/day

GEn 1200mg/day

gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks

Group Type EXPERIMENTAL

GEn 1200mg/day

Intervention Type DRUG

gabapentin enacarbil 1200mg/day

GEn 2400mg/day

gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks

Group Type EXPERIMENTAL

GEn 2400mg/day

Intervention Type DRUG

gabapentin enacarbil 2400mg/day

GEn 3600mg/day

gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks

Group Type EXPERIMENTAL

GEn 3600mg/day

Intervention Type DRUG

gabapentin enacarbil 3600mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

placebo

Intervention Type DRUG

GEn 1200mg/day

gabapentin enacarbil 1200mg/day

Intervention Type DRUG

GEn 2400mg/day

gabapentin enacarbil 2400mg/day

Intervention Type DRUG

GEn 3600mg/day

gabapentin enacarbil 3600mg/day

Intervention Type DRUG

Pregabalin

pregabalin 300mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

XP13512 GSK1838262 gabapentin enacarbil gabapentin enacarbil GSK1838262 XP13512 XP13512 GSK1838262 gabapentin enacarbil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years or older
* Female subjects are eligible to enter if of non-childbearing potential or not lactating, has a negative pregnancy test and agrees to use a specified highly effective method for avoiding pregnancy
* Documented medical diagnosis of Type 1 or 2 diabetes including:
* Stable glycemic control for 3 months defined as \<25% change of routine insulin, \<50% change of routine oral anti-diabetic agent dose and HbA1c \< 8%. (HbA1c of 8 to 11% eligible if attempts to improve diabetic control failed)
* DPN defined by:
* Bilateral reduced or absent reflexes at the ankles, or
* Bilateral impaired vibration, pinprick, fine touch or temperature perception in the distal lower extremities And
* Persistent distal burning or dull pain in the feet, or
* Persistent proximal aching pain in the legs, or
* Paroxysmal electric, shooting, stabbing pain, or
* Dysasthesias, or
* Evoked pain And
* history of pain for at least six months and no greater than five years attributed to DPN (refers to duration of pain)
* Baseline 24-hour average daily pain intensity score \>4.0 as measured on an 11 point pain intensity numerical rating scale
* Provides written informed consent in accordance with all applicable regulatory requirements

Exclusion Criteria

* Other chronic pain conditions not associated with DPN. However, the subject will not be excluded if:
* The pain condition is located at a different region of the body, and
* The pain intensity of this condition is not greater than the pain intensity of the DPN, and
* The subject can assess their DPN independently of other pain condition.
* Other causes of neuropathy or lower extremity pain
* Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study
* Hepatic impairment defined as ALT or AST \> 2x upper limit of normal (ULN) or alkaline phosphatase or bilirubin \> 1.5x ULN
* Chronic hepatitis B or C
* Impaired renal function defined as either creatinine clearance \< 60 mL/min or requiring hemodialysis
* Corrected QT (QTc) interval \>450 msec or QTc interval \>480 msec for patients with Bundle Branch Block
* Uncontrolled hypertension at screen (sitting systolic \>160 mmHg and/or sitting diastolic \>90 mmHg
* Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drug(s)
* Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn or pregabalin, or, in the investigator's judgment:
* Is considered to be clinically significant and could pose a safety concern or,
* Could interfere with the accurate assessment of safety or efficacy, or,
* Could potentially affect a subject's safety or study outcome
* Meets criteria defined by the DSM-IV-TR for a major depressive episode or for active significant psychiatric disorders within last year
* Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication
* Antidepressant medication may not be changed or discontinued to met entry criteria and must be stable for at least 3 months prior to enrollment
* History of clinically significant drug or alcohol abuse (DSM-IV-TR). Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted
* Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device
* Has participated in a clinical study and was exposed to investigational or non-investigational drug or device:
* Within preceding month for studies unrelated to DPN, or
* Within six months for studies related to DPN
* Treated previously with GEn
* History of allergic or medically significant adverse reaction to investigational products (including gabapentin or pregabalin) or their excipients, acetaminophen or related compounds
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

XenoPort, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Newport Beach, California, United States

Site Status

GSK Investigational Site

Northridge, California, United States

Site Status

GSK Investigational Site

Oxnard, California, United States

Site Status

GSK Investigational Site

Riverside, California, United States

Site Status

GSK Investigational Site

San Diego, California, United States

Site Status

GSK Investigational Site

Santa Ana, California, United States

Site Status

GSK Investigational Site

Alabaster, Alabama, United States

Site Status

GSK Investigational Site

Birmingham, Alabama, United States

Site Status

GSK Investigational Site

Dothan, Alabama, United States

Site Status

GSK Investigational Site

Hoover, Alabama, United States

Site Status

GSK Investigational Site

Jasper, Alabama, United States

Site Status

GSK Investigational Site

Muscle Shoals, Alabama, United States

Site Status

GSK Investigational Site

Northport, Alabama, United States

Site Status

GSK Investigational Site

Tuscaloosa, Alabama, United States

Site Status

GSK Investigational Site

Mesa, Arizona, United States

Site Status

GSK Investigational Site

Peoria, Arizona, United States

Site Status

GSK Investigational Site

Tempe, Arizona, United States

Site Status

GSK Investigational Site

Hot Springs, Arkansas, United States

Site Status

GSK Investigational Site

Little Rock, Arkansas, United States

Site Status

GSK Investigational Site

Anaheim, California, United States

Site Status

GSK Investigational Site

Concord, California, United States

Site Status

GSK Investigational Site

Escondido, California, United States

Site Status

GSK Investigational Site

Fresno, California, United States

Site Status

GSK Investigational Site

Huntington Park, California, United States

Site Status

GSK Investigational Site

La Jolla, California, United States

Site Status

GSK Investigational Site

Los Gatos, California, United States

Site Status

GSK Investigational Site

Mission Viejo, California, United States

Site Status

GSK Investigational Site

Santa Monica, California, United States

Site Status

GSK Investigational Site

Temecula, California, United States

Site Status

GSK Investigational Site

Walnut Creek, California, United States

Site Status

GSK Investigational Site

Westlake Village, California, United States

Site Status

GSK Investigational Site

Brandon, Florida, United States

Site Status

GSK Investigational Site

Clearwater, Florida, United States

Site Status

GSK Investigational Site

Fort Lauderdale, Florida, United States

Site Status

GSK Investigational Site

Fort Myers, Florida, United States

Site Status

GSK Investigational Site

Hallandale, Florida, United States

Site Status

GSK Investigational Site

Hollywood, Florida, United States

Site Status

GSK Investigational Site

New Port Richey, Florida, United States

Site Status

GSK Investigational Site

Ocala, Florida, United States

Site Status

GSK Investigational Site

Ormond Beach, Florida, United States

Site Status

GSK Investigational Site

Pembroke Pines, Florida, United States

Site Status

GSK Investigational Site

St. Petersburg, Florida, United States

Site Status

GSK Investigational Site

Tallahassee, Florida, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Decatur, Georgia, United States

Site Status

GSK Investigational Site

Marietta, Georgia, United States

Site Status

GSK Investigational Site

Roswell, Georgia, United States

Site Status

GSK Investigational Site

Chicago, Illinois, United States

Site Status

GSK Investigational Site

Libertyville, Illinois, United States

Site Status

GSK Investigational Site

Evansville, Indiana, United States

Site Status

GSK Investigational Site

Evansville, Indiana, United States

Site Status

GSK Investigational Site

Wichita, Kansas, United States

Site Status

GSK Investigational Site

Rockville, Maryland, United States

Site Status

GSK Investigational Site

Wellesley Hills, Massachusetts, United States

Site Status

GSK Investigational Site

Kalamazoo, Michigan, United States

Site Status

GSK Investigational Site

Olive Branch, Mississippi, United States

Site Status

GSK Investigational Site

Kansas City, Missouri, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

Las Vegas, Nevada, United States

Site Status

GSK Investigational Site

Las Vegas, Nevada, United States

Site Status

GSK Investigational Site

Albuquerque, New Mexico, United States

Site Status

GSK Investigational Site

Albuquerque, New Mexico, United States

Site Status

GSK Investigational Site

Flushing, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

North Massapequa, New York, United States

Site Status

GSK Investigational Site

Rochester, New York, United States

Site Status

GSK Investigational Site

Staten Island, New York, United States

Site Status

GSK Investigational Site

Greensboro, North Carolina, United States

Site Status

GSK Investigational Site

Raleigh, North Carolina, United States

Site Status

GSK Investigational Site

Salisbury, North Carolina, United States

Site Status

GSK Investigational Site

Toledo, Ohio, United States

Site Status

GSK Investigational Site

Norman, Oklahoma, United States

Site Status

GSK Investigational Site

Eugene, Oregon, United States

Site Status

GSK Investigational Site

Medford, Oregon, United States

Site Status

GSK Investigational Site

Levittown, Pennsylvania, United States

Site Status

GSK Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

GSK Investigational Site

Greer, South Carolina, United States

Site Status

GSK Investigational Site

Mt. Pleasant, South Carolina, United States

Site Status

GSK Investigational Site

Kingsport, Tennessee, United States

Site Status

GSK Investigational Site

Houston, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

Alexandria, Virginia, United States

Site Status

GSK Investigational Site

Richmond, Virginia, United States

Site Status

GSK Investigational Site

Weber City, Virginia, United States

Site Status

GSK Investigational Site

Spokane, Washington, United States

Site Status

GSK Investigational Site

Spokane, Washington, United States

Site Status

GSK Investigational Site

Tacoma, Washington, United States

Site Status

GSK Investigational Site

Vancouver, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Rauck R, Makumi CW, Schwartz S, Graff O, Meno-Tetang G, Bell CF, Kavanagh ST, McClung CL. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013 Jul;13(6):485-96. doi: 10.1111/papr.12014. Epub 2012 Nov 27.

Reference Type DERIVED
PMID: 23186035 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

110448

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
NCT01057693 COMPLETED PHASE3
Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.
NCT00311363 COMPLETED PHASE3
Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
NCT01332305 COMPLETED PHASE2
A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy
NCT06383702 NOT_YET_RECRUITING PHASE3
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553475 COMPLETED PHASE3
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
NCT01411124 COMPLETED PHASE1
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
NCT01455415 COMPLETED PHASE3
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
NCT00159679 COMPLETED PHASE4
To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
NCT00150423 COMPLETED PHASE3
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156 COMPLETED PHASE3
Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy
NCT00712439 COMPLETED PHASE2
A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy
NCT00644748 COMPLETED PHASE4
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)
NCT01474772 COMPLETED PHASE3
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
NCT01332149 COMPLETED PHASE3
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
NCT00570310 COMPLETED PHASE1
A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
NCT00629681 COMPLETED PHASE4
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
NCT00141401 COMPLETED PHASE3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553280 COMPLETED PHASE3
Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine
NCT01476124 COMPLETED PHASE1
Comparison of Gabapentin and Pregabalin for Radicular Pain
NCT02064790 COMPLETED
A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy
NCT00573261 COMPLETED PHASE4
Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy
NCT01770964 UNKNOWN PHASE4
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
NCT00333359 COMPLETED PHASE3
A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
NCT05624853 COMPLETED PHASE4
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
NCT01939366 COMPLETED PHASE2